Down-regulation of proteasomal subunit MB1 is an independent predictor of improved survival in ovarian cancer

Gynecologic Oncology

Volumn 113, Issue 2, 2009, Pages 256-263

  Leffers, Ninke ^a   Gooden, Marloes J M ^a   Mokhova, Anna A ^a   Kast, W Martin ^b   Boezen, H Marike ^a   ten Hoor, Klaske A ^a   Hollema, Harry ^a   Daemen, Toos ^a   van der Zee, Ate G J ^a   Nijman, Hans W ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Antigen presentation; Antigen processing; MB1; Ovarian cancer; Proteasome

Indexed keywords

ALPHA 1 MICROGLOBULIN; ANTINEOPLASTIC METAL COMPLEX; BETA 2 MICROGLOBULIN; ENDOPLASMIC RETICULUM AMINOPEPTIDASE 1; HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; LMP7 PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MB1 PROTEIN; PROTEASOME; TAXANE DERIVATIVE; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 1; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 2; UNCLASSIFIED DRUG;

ANTIGEN PRESENTATION; ARTICLE; CANCER CHEMOTHERAPY; CELL NUCLEUS; CYTOPLASM; DOWN REGULATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL; TISSUE MICROARRAY;

AMINOPEPTIDASES; ANTIGEN PRESENTATION; ANTIGENS, CD79; ATP-BINDING CASSETTE TRANSPORTERS; DOWN-REGULATION; FEMALE; HLA-A ANTIGENS; HLA-B ANTIGENS; HLA-C ANTIGENS; HUMANS; MIDDLE AGED; MULTIENZYME COMPLEXES; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN DISULFIDE-ISOMERASES;

EID: 64149122759     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.12.030     Document Type: Article

References (46)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 55 2 (2005 Mar) 74-108
2. Zhang L., Conejo-Garcia J.R., Katsaros D., Gimotty P.A., Massobrio M., Regnani G., et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348 3 (2003 Jan 16) 203-213
3. Coukos G., Conejo-Garcia J.R., Roden R.B., and Wu T.C. Immunotherapy for gynaecological malignancies. Expert Opin. Biol. Ther. 5 9 (2005 Sep) 1193-1210
4. Guppy A.E., Nathan P.D., and Rustin G.J. Epithelial ovarian cancer: a review of current management. Clin. Oncol. (R. Coll. Radiol.) 17 6 (2005 Sep) 399-411
5. Chiriva-Internati M., Weidanz J.A., Yu Y., Frezza E.E., Jenkins M.R., Kennedy R.C., et al. Sperm protein 17 is a suitable target for adoptive T-cell based immunotherapy in human ovarian cancer. J Immunother 31 8 (2008 Oct) 693-703
6. Mayordomo J.I., Loftus D.J., Sakamoto H., De Cesare C.M., Appasamy P.M., Lotze M.T., et al. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J. Exp. Med. 183 4 (1996 Apr 1) 1357-1365
7. Nikitina E.Y., Chada S., Muro-Cacho C., Fang B., Zhang R., Roth J.A., et al. An effective immunization and cancer treatment with activated dendritic cells transduced with full-length wild-type p53. Gene Ther. 9 5 (2002 Mar) 345-352
8. Antonia S.J., Mirza N., Fricke I., Chiappori A., Thompson P., Williams N., et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin. Cancer Res. 12 3 Pt 1 (2006 Feb 1) 878-887
9. Svane I.M., Pedersen A.E., Johansen J.S., Johnsen H.E., Nielsen D., Kamby C., et al. Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers. Cancer Immunol. Immunother. 56 9 (2007 Sep) 1485-1499
10. Bangia N., and Ferrone S. Antigen presentation machinery (APM) modulation and soluble HLA molecules in the tumor microenvironment: do they provide tumor cells with escape mechanisms from recognition by cytotoxic T lymphocytes?. Immunol. Invest. 35 3-4 (2006) 485-503
11. Seliger B., Maeurer M.J., and Ferrone S. Antigen-processing machinery breakdown and tumor growth. Immunol. Today 21 9 (2000 Sep) 455-464
12. Coux O., Tanaka K., and Goldberg A.L. Structure and functions of the 20S and 26S proteasomes. Annu. Rev. Biochem. 65 (1996) 801-847
13. Kloetzel P.M., and Ossendorp F. Proteasome and peptidase function in MHC-class-I-mediated antigen presentation. Curr. Opin. Immunol. 16 1 (2004 Feb) 76-81
14. Purcell A.W., and Elliott T. Molecular machinations of the MHC-I peptide loading complex. Curr. Opin. Immunol. 20 1 (2008 Feb) 75-81
15. Cascio P., Hilton C., Kisselev A.F., Rock K.L., and Goldberg A.L. 26S proteasomes and immunoproteasomes produce mainly N-extended versions of an antigenic peptide. EMBO J. 20 10 (2001 May 15) 2357-2366
16. Rivett A.J., and Hearn A.R. Proteasome function in antigen presentation: immunoproteasome complexes, peptide production, and interactions with viral proteins. Curr. Protein Pept. Sci. 5 3 (2004 Jun) 153-161
17. Dahlmann B. Role of proteasomes in disease. BMC Biochem. 8 Suppl 1 (2007) S3
18. Ritz U., Momburg F., Pircher H.P., Strand D., Huber C., and Seliger B. Identification of sequences in the human peptide transporter subunit TAP1 required for transporter associated with antigen processing (TAP) function. Int. Immunol. 13 1 (2001 Jan) 31-41
19. Chang S.C., Momburg F., Bhutani N., and Goldberg A.L. The ER aminopeptidase, ERAP1, trims precursors to lengths of MHC class I peptides by a "molecular ruler" mechanism. Proc. Natl. Acad. Sci. U. S. A. 102 47 (2005 Nov 22) 17107-17112
20. Cresswell P., Androlewicz M.J., and Ortmann B. Assembly and transport of class I MHC-peptide complexes. Ciba Found. Symp. 187 (1994) 150-162
21. Garbi N., Tanaka S., van den Broek M., Momburg F., and Hammerling G.J. Accessory molecules in the assembly of major histocompatibility complex class I/peptide complexes: how essential are they for CD8(+) T-cell immune responses?. Immunol. Rev. 207 (2005 Oct) 77-88
22. Atkins D., Breuckmann A., Schmahl G.E., Binner P., Ferrone S., Krummenauer F., et al. MHC class I antigen processing pathway defects, ras mutations and disease stage in colorectal carcinoma. Int. J. Cancer 109 2 (2004 Mar 20) 265-273
23. Atkins D., Ferrone S., Schmahl G.E., Storkel S., and Seliger B. Down-regulation of HLA class I antigen processing molecules: an immune escape mechanism of renal cell carcinoma?. J. Urol. 171 2 Pt 1 (2004 Feb) 885-889
24. Campoli M., Chang C.C., Oldford S.A., Edgecombe A.D., Drover S., and Ferrone S. HLA antigen changes in malignant tumors of mammary epithelial origin: molecular mechanisms and clinical implications. Breast Dis. 20 (2004) 105-125
25. Gobbi G., Mirandola P., Micheloni C., Solenghi E., Sponzilli I., Artico M., et al. Expression of HLA class I antigen and proteasome subunits LMP-2 and LMP-10 in primary vs. metastatic breast carcinoma lesions. Int. J. Oncol. 25 6 (2004 Dec) 1625-1629
26. Johnsen A.K., France J., Nagy N., Askew D., Abdul-Karim F.W., Gerson S.L., et al. Systemic deficits in transporter for antigen presentation (TAP)-1 or proteasome subunit LMP2 have little or no effect on tumor incidence. Int. J. Cancer 91 3 (2001 Feb 1) 366-372
27. Kageshita T., Hirai S., Ono T., Hicklin D.J., and Ferrone S. Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression. Am. J. Pathol. 154 3 (1999 Mar) 745-754
28. Mehta A.M., Jordanova E.S., Kenter G.G., Ferrone S., and Fleuren G.J. Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma. Cancer Immunol. Immunother. 57 (2008) 197-206
29. Miyagi T., Tatsumi T., Takehara T., Kanto T., Kuzushita N., Sugimoto Y., et al. Impaired expression of proteasome subunits and human leukocyte antigens class I in human colon cancer cells. J. Gastroenterol. Hepatol. 18 1 (2003 Jan) 32-40
30. Ritz U., Momburg F., Pilch H., Huber C., Maeurer M.J., and Seliger B. Deficient expression of components of the MHC class I antigen processing machinery in human cervical carcinoma. Int. J. Oncol. 19 6 (2001 Dec) 1211-1220
31. Seliger B., Ritz U., Abele R., Bock M., Tampe R., Sutter G., et al. Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway. Cancer Res. 61 24 (2001 Dec 15) 8647-8650
32. So T., Takenoyama M., Mizukami M., Ichiki Y., Sugaya M., Hanagiri T., et al. Haplotype loss of HLA class I antigen as an escape mechanism from immune attack in lung cancer. Cancer Res. 65 13 (2005 Jul 1) 5945-5952
33. Han L.Y., Fletcher M.S., Urbauer D.L., Mueller P., Landen C.N., Kamat A.A., et al. HLA class I antigen processing machinery component expression and intratumoral T-cell infiltrate as independent prognostic markers in ovarian carcinoma. Clin. Cancer Res. 14 11 (2008 Jun 1) 3372-3379
34. Camp R.L., Charette L.A., and Rimm D.L. Validation of tissue microarray technology in breast carcinoma. Lab. Invest. 80 12 (2000 Dec) 1943-1949
35. Hendriks Y., Franken P., Dierssen J.W., De L.W., Wijnen J., Dreef E., et al. Conventional and tissue microarray immunohistochemical expression analysis of mismatch repair in hereditary colorectal tumors. Am. J. Pathol. 162 2 (2003 Feb) 469-477
36. Rosen D.G., Huang X., Deavers M.T., Malpica A., Silva E.G., and Liu J. Validation of tissue microarray technology in ovarian carcinoma. Mod. Path. 17 7 (2004 Jul) 790-797
37. Ruiter D.J., Ferrier C.M., Van Muijen G.N., Henzen-Logmans S.C., Kennedy S., Kramer M.D., et al. Quality control of immunohistochemical evaluation of tumour-associated plasminogen activators and related components. European BIOMED-1 concerted action on clinical relevance of proteases in tumour invasion and metastasis. Eur. J. Cancer 34 9 (1998 Aug) 1334-1340
38. Meissner M., Reichert T.E., Kunkel M., Gooding W., Whiteside T.L., Ferrone S., et al. Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome. Clin. Cancer Res. 11 7 (2005 Apr 1) 2552-2560
39. Murakami Y., Kanda K., Yokota K., Kanayama H., and Kagawa S. Prognostic significance of immuno-proteosome subunit expression in patients with renal-cell carcinoma: a preliminary study. Mol. Urol. 5 3 (2001) 113-119
40. Belich M.P., Glynne R.J., Senger G., Sheer D., and Trowsdale J. Proteasome components with reciprocal expression to that of the MHC-encoded LMP proteins. Curr. Biol. 4 9 (1994 Sep 1) 769-776
41. Frankel A., Man S., Elliott P., Adams J., and Kerbel R.S. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin. Cancer Res. 6 9 (2000 Sep) 3719-3728
42. Cusack Jr. J.C., Liu R., Houston M., Abendroth K., Elliott P.J., Adams J., et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res. 61 9 (2001 May 1) 3535-3540
43. Khan A.N., Gregorie C.J., and Tomasi T.B. Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells. Cancer Immunol. Immunother. 57 5 (2008 May) 647-654
44. Rolland P., Deen S., Scott I., Durrant L., and Spendlove I. Human leukocyte antigen class I antigen expression is an independent prognostic factor in ovarian cancer. Clin. Cancer Res. 13 12 (2007 Jun 15) 3591-3596
45. Ogino T., Shigyo H., Ishii H., Katayama A., Miyokawa N., Harabuchi Y., et al. HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker. Cancer Res. 66 18 (2006 Sep 15) 9281-9289
46. Leffers N., Gooden M.J., De Jong R.A., Hoogeboom B.N., ten Hoor K.A., Hollema H., et al. Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol Immunother 58 3 (2009 Mar) 449-459